Prediction of Diffuse High-Grade Glioma Survival Outcomes Using Preoperative Whole-Brain Tractography-Based Resectability Metrics
- PMID: 40772761
- DOI: 10.1227/neu.0000000000003668
Prediction of Diffuse High-Grade Glioma Survival Outcomes Using Preoperative Whole-Brain Tractography-Based Resectability Metrics
Abstract
Background and objectives: Extent of resection (EOR) is a recognized predictor of survival in adults with diffuse high-grade glioma (HGG) but can only be calculated postoperatively. We developed novel whole-brain tractography (WBT)-based metrics to quantify tumor resectability and predict survival outcomes using only preoperative data.
Methods: Consecutive adults with biopsied or resected HGGs were retrospectively reviewed. Unresectable tumor volume (UTV) was the total overlapping volume of tumor with eloquent tracts and deep brain structures. Resectability index (RI) was (preoperative tumor volume [PTV]-UTV)/PTV, where PTV was preresection tumor volume. Modified metrics (mRI and mUTV) considered only the corticospinal tract and left arcuate fasciculus. Progression-free and overall survival (OS) were modeled using Cox proportional hazards and accelerated failure time (AFT) multivariable regression.
Results: We analyzed 146 tumors, of which 84 had preoperative WBT available. Both mRI (area under receiver operating characteristic curve = 0.953) and mUTV (area under receiver operating characteristic curve = 0.854) had robust accuracy in predicting biopsy vs resection at cutoff values of 0.75 and 2.5 cm3, respectively. Tumors with the mRI above and below 0.65 had the most significant difference in median OS (not reached vs 82 days, P < .0001). The best-performing AFT model of OS using only preoperative covariates was a log-logistic AFT model (k-fold validated mean C-index = 0.788), in which mUTV was an independent predictor of outcome (P = .008). Postoperative OS models using WBT-based resectability metrics exhibited significantly higher mean C-indices compared with those using the conventional metrics, EOR and residual tumor volume (0.927 vs 0.874, P < .001).
Conclusion: Our patient-specific WBT-based HGG resectability metrics closely approximate EOR and residual tumor volume, can be calculated on preoperative imaging, and are strong predictors of survival outcomes after HGG biopsy or resection.
Keywords: Biopsy; Extent of resection; High-grade diffuse glioma; Survival modeling; Survival outcomes; Tumor burden; White matter tractography.
Copyright © Congress of Neurological Surgeons 2025. All rights reserved.
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.J Neurooncol. 2022 Jan;156(2):233-256. doi: 10.1007/s11060-021-03901-9. Epub 2022 Jan 6. J Neurooncol. 2022. PMID: 34989964
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
References
-
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
-
- Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495-503.
-
- Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460-1469.
-
- McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463-470; discussion 469-470.
-
- Rahman M, Abbatematteo J, De Leo EK, et al. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg. 2017;127(1):123-131.
LinkOut - more resources
Full Text Sources